<DOC>
	<DOCNO>NCT00437684</DOCNO>
	<brief_summary>The purpose study evaluate combination Lpv/r monotherapy anti-HCV drug match additional toxicity induce association HAART Peg-IFN + ritonavir HIV/HCV coinfected patient . Secondary objective ass Lpv/r monotherapy HCV-treatment associate HIV efficacy versus optimize HAART .</brief_summary>
	<brief_title>Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy ( HAART ) HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus ( HCV ) Therapy</brief_title>
	<detailed_description>This pilot , randomise , open label , control clinical trial . All eligible patient ( CD4 &gt; 350 , HIV RNA &lt; 50 copy PI mutation ) randomize ( 1:1 ) receive LPV/r new tab ( 200/50 mg , 2 cpr BID ) monotherapy ( arm A ) LPV/r + select NUCS ( arm B ) associate anti-HCV therapy 12 month . The number subject recruit , arm study , equal 25 , total number subject enrol 50 . - Group A : receive LPV/r monotherapy anti HCV drug 12 month . - Group B : receive LPV/r+ select NUCS anti HCV drug 12 month . All patient followed-up six month end anti-HCV drug evaluation Sustained Virological Response ( SVR ) . At end co-treatment HCV/HIV , subject treat HIV infection accord physician decisions.As anti-HCV drug patient receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At end third month combine therapy , patient reach early virological response continue anti-HCV drug .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Subject &gt; 18 year old Subject give write informed consent Subject confirm diagnosis HIV HCV infection Subject naive HCVinfection treatment Subject chronic hepatitis and/or subject compensate cirrhosis ( Child class A ) Subject CD4+ count &gt; 350 cell/mmc Subject HIVRNA negative previous six month Subject stable HAART include r/LPV &gt; 6 month Subject genotype available baseline mutation associate resistance PI virologic failure PI treatment , define confirm HIVRNA level &gt; 50 cp/mL 24 week , &gt; 50 cp/ml 48 week , repeat HIV RNA level &gt; 50 cp/mL prior suppression viremia &lt; 50 cps/mL . Free clinically significant disease ( HIV HCV ) would interfere study evaluation . Subject use effective contraceptive method duration study Subject HbsAg positive Subject cirrhosis score ChildPugh B/C , No previous hepatic decompensation Subject HIVrelated thrombocytopenia ( Platelets count &lt; 50.000/mmc ) Subject neutrophils count &lt; 1500/mmc Subject Hb value &lt; 11 g/dL Subject creatinine value &gt; 1.5 mg/dL Subject pregnant wish become Subject cause liver disease chronic hepatitis C , status liver decompensation condition consistent decompensated liver disease ( bleed esophageal varix , sign current bleeding , significant ascites , hepatic encephalopathy ) Subject alcohol abuser ( &gt; 30 gr/die ) Subject autoimmune hepatitis Prior treatment PEGIFN ribavirin Illicit drug abuse opinion investigator could lead poor compliance term protocol ( Methadone sostitution therapy allow ) Active heart disease ( e.g . angina , congestive heart failure , recent myocardial infarction significant arrhythmia ) Subject preexist severe depression , condition severe psychiatric disorder suicidal ideation , suicide attempt , depression acute psychosis Subject uncompensated diabetes Subject active opportunistic infection major opportunistic infection previous 12 month Subject know hypersensitivity contraindication study medication Subject condition opinion investigator make subject unsuitable enrolment interfere subject participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>HIV/HCV</keyword>
	<keyword>HIV HCV coinfected patient</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>